SCHEMBL1911222

SCHEMBL1911222

CCOC(=O)CNC(=O)N[C@@H]1CCN(C)C1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.51
SSTR4 P31391 8/20 0.40
PPID Q08752 2/20 0.40
PPIB P23284 1/20 0.40
PPIA P62937 1/20 0.40
PPIG Q13427 1/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SSTR1 P30872 4/20 0.39
CYP17A1 P05093 1/20 0.39
CYP21A2 P08686 1/20 0.39
CYP11B1 P15538 1/20 0.39
NLRP3 Q96P20 1/20 0.38
THRB P10828 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13242296 0.81 MTNR1A (0.45) EPHX2SSTR4KDM4ESSTR1
SCHEMBL357376 0.81 MTNR1A (0.45) EPHX2SSTR4KDM4ESSTR1
SCHEMBL13686518 0.79 HSD11B1 (0.53) SSTR4SSTR1THRBATML3MBTL1
SCHEMBL17286067 0.76 KDM4E (0.46) EPHX2SSTR4GAAKDM4ETHRB
SCHEMBL10258892 0.72 EPHX2 (0.44) EPHX2KDM4ETHRBATML3MBTL1
SCHEMBL13804064 0.72 MTNR1A (0.42) EPHX2SSTR4SSTR1
SCHEMBL1749205 0.71 SSTR4 (0.44) SSTR4KDM4ESSTR1
SCHEMBL4202085 0.71 SSTR4 (0.44) SSTR4KDM4ESSTR1
SCHEMBL1189936 0.71 SSTR4 (0.44) SSTR4KDM4ESSTR1
SCHEMBL13242297 0.71 DRD2 (0.44) EPHX2SSTR4SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318750-B2 Organic compounds NOVARTIS AG (NL) 2012-11-27 US disclosed
US-8318750-B2 Organic compounds NOVARTIS AG (NL) 2012-11-27 US disclosed
US-8258141-B2 Organic compounds NOVARTIS AG (CH) 2012-09-04 US disclosed
US-8258141-B2 Organic compounds NOVARTIS AG (CH) 2012-09-04 US disclosed
US-20120004212-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
US-20120004212-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
US-20120004247-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
US-20120004247-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
US-20100286126-A1 Organic Compounds NOVARTIS AG (CH) 2010-11-11 US disclosed
US-20100286126-A1 Organic Compounds NOVARTIS AG (CH) 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286126-A1 Organic Compounds CYP3A43, SLCO1B3, CYP2C19 EPHX2 2731/4885SSTR4 418/4885PPID 2043/4885
US-20120004212-A1 ORGANIC COMPOUNDS CYP3A43, SLCO1B3, CYP2C19 EPHX2 2731/4885SSTR4 418/4885PPID 2043/4885
US-20120004247-A1 ORGANIC COMPOUNDS CYP3A43, SLCO1B3, CYP2C19 EPHX2 2731/4885SSTR4 418/4885PPID 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.